Intelligent Bio Solutions Partners with PREMIUM for Manufacturing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2025
0mins
Source: Yahoo Finance
- Partnership Announcement: Intelligent Bio Solutions has entered into a manufacturing partnership with PREMIUM, aimed at enhancing production capabilities and market responsiveness, thereby expanding its influence in the biotechnology sector.
- Market Potential: This collaboration will enable Intelligent Bio Solutions to leverage PREMIUM's advanced manufacturing technologies, which is expected to significantly improve product quality and production efficiency, strengthening its position in a competitive market.
- Strategic Implications: By partnering with PREMIUM, Intelligent Bio Solutions can not only optimize its supply chain management but also accelerate time-to-market for new products, addressing the growing market demand effectively.
- Future Outlook: The establishment of this partnership signifies Intelligent Bio Solutions' ongoing expansion in the biotechnology industry, which is anticipated to generate new revenue streams and long-term growth opportunities for the company.
Analyst Views on INBS
About INBS
Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








